基于Renovac-A Dimer RBD的抗冠状病毒子单位疫苗的开发,临床前安全性和免疫特征
Muzaffar Muminov1, Nargiza Tsiferova1,2, Egor Pshenichnov1
1Center for Advanced Technologies, Tashkent 100174, Uzbekistan.
Vaccines
|January 8, 2025
概括
一种新的亚单元候选疫苗,RENOVAC,在动物模型中证明了安全性和免疫性. 这种COVID-19候选疫苗有效地产生了特定的免疫球蛋白和中和抗体,为临床试验铺平了道路.
科学领域:
- 疫苗学 疫苗学 疫苗学
- 免疫学 免疫学 免疫学
- 临床前研究 临床前研究
背景情况:
- 疫苗开发对于传染病控制至关重要,特别是在发展中国家.
- 评估疫苗的安全性和免疫性是全球卫生安全的关键.
- 现有的COVID-19疫苗强调了需要强大的开发平台.
研究的目的:
- 开发和评估一种新的局部亚单元候选疫苗RENOVAC的安全性和免疫性.
- 在临床前动物模型中评估RENOVAC的毒性和免疫反应概况.
主要方法:
- 一个编码配对受体结合域 (RBD) 与GS链接器的合成基因被克隆并表达在CHO细胞中.
- 纯化蛋白质被配制成10微克/剂量和25微克/剂量疫苗,用于毒性和免疫性测试.
- 斯普拉格·道利大鼠接受了肌肉内注射,以评估14天的重复剂量毒性和免疫反应.
主要成果:
- 在高达25μg/动物的剂量下,RENOVAC的耐受性很好,没有显著的不良毒理发现.
- 疫苗诱导了高水平的特定免疫球蛋白 (IGs) 和中和抗体 (NAbs).
- 免疫反应涉及CD4+Th2细胞激活,导致B细胞激活和幽默免疫.
结论:
- 在临床前研究中,RENOVAC表现出可接受的安全性和可靠的免疫性.
- 疫苗的概况支持其进入临床试验以进行进一步评估.
- 这项研究有助于开发有效的疫苗平台,以提高卫生安全.
相关概念视频
Cross-reactivity
Overview
Vaccinations
Overview
Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Respiratory Syncytial Virus Disease
Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...


